Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones

European Journal of Medicinal Chemistry

Volumn 44, Issue 1, 2009, Pages 303-311

  Balzarini, Jan ^a   Orzeszko Krzesińska, Barbara ^b   Maurin, Jan K ^c,d   Orzeszko, Andrzej ^e,f  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF ATOMIC ENERGY   (Poland)

^d NATIONAL MEDICINES INSTITUTE   (Poland)

^e WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^f MILITARY UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Adamantane derivatives; Anti HIV activity; NNRTIs; Thiazolidin 4 ones

Indexed keywords

2 ADAMANTAN 1 YL 3 (4,6 DIMETHYLPYRIMIDIN 2 YL)THIAZOLIDIN 4 ONE; ADAMANTANE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZOLIDIN 4 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTUM CHEMISTRY; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; VIRUS INHIBITION;

ADAMANTANE; ANTI-HIV AGENTS; CELL LINE; CYTOSTATIC AGENTS; HIV-1; HUMANS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES;

EID: 57949109639     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.02.039     Document Type: Article

References (18)

1. Balzarini J., Orzeszko B., Maurin J.K., and Orzeszko A. Eur. J. Med. Chem. 42 (2007) 993-1003
2. de Corte B.L. J. Med. Chem. 48 (2005) 1689-1696
3. Venkatachalam T.K., Mao C., and Uckun F.M. Bioorg. Med. Chem. 12 (2004) 4275-4284
4. Barreca M.L., Chimirri A., De Luca L., Monforte A.M., Monforte P., Rao A., Zappala M., Balzarini J., De Clercq E., Pannecouque C., and Witvrouw M. Bioorg. Med. Chem. Lett. 11 (2001) 1793-1796
5. Rao A., Balzarini J., Carbone A., Chimirri A., De Clercq E., Monforte A.M., Monforte P., Pannecouque C., and Zapalla M. Antivir. Res. 63 (2004) 79-84
6. Barreca M.L., Balzarini J., Chimirri A., De Clercq E., De Luca L., Höltje H.D., Höltje M., Monforte A.M., Monforte P., Pannecouque C., Rao A., and Zappala M. J. Med. Chem. 45 (2002) 5410-5413
7. Rao A., Balzarini J., Carbone A., Chimirri A., De Clercq E., Monforte A.M., Monforte P., Pannecouque C., and Zapalla M. Farmaco 59 (2004) 33-39
8. Rao A., Balzarini J., Carbone A., Chimirri A., De Clercq E., Monforte A.M., Monforte P., Pannecouque C., and Zapalla M. Farmaco 57 (2002) 747-751
9. Mancuso A.J., and Swern D. Synthesis (1981) 165-185
10. Mitsunobu O. Synthesis (1981) 1-28
11. Zoidis G., Fytas C., Papanastasiou I., Foscolos G.B., Fytas G., Padalko E., de Clercq E., Naesens L., Neyts J., and Kolocouris N. Bioorg. Med. Chem. 14 (2006) 3341-3348
12. Kolocouris N., Zoidis G., Foscolos G.B., Fytas G., Prathalingham S.R., Kelly J.M., Naesens L., and De Clercq E. Bioorg. Med. Chem. Lett. 17 (2007) 4358-4362
13. Basavapathruni A., and Anderson K.S. Curr. Pharm. Des. 12 (2006) 1857-1865
14. De Clercq E. Collect. Czech. Chem. Commun. 63 (1998) 449-479
15. Luly J.R., Dellaria J.F., Plattner J.J., Soderquist J.L., and Yi N. J. Org. Chem. 52 (1987) 1487-1492
16. Aldrich P.E., Hermann E.C., Meier W.E., Paulshock M., Prichard W.W., Snyder J.A., and Watts J.C. J. Med. Chem. 14 (1971) 535-543
17. Sheldrick G.M. SHELXS-97, Program for X-ray Structure Solution (1997), University of Göttingen, Germany
18. Sheldrick G.M. SHELXL-97, Program for X-ray Structure Refinement (1997), University of Göttingen, Germany